Sumgen Biotech Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2015

Location

Hangzhou Zhejiang China

Primary Industry

Biotechnology

About

Based in Hangzhou, China, and founded in 2015, Hangzhou Sumgen Biotech Co., Ltd. trading as Sumgen Biotech is a biopharmaceutical company dedicated to the creation and commercialization of antibody therapeutics for cancer and other serious diseases. In December 2021, Sumgen Biotech raised over CNY 200 million in series B+ funding from China National Biotec Group, Shenzhen Qianhai Junchuan Investment Management, Sitong Capital, Wanhuixin Fund, Zheshang Venture Capital, and returning investors Addor Capital, HanKang Capital and Sinopharm Capital. As of November 2022, the company has three R&D centers in Hangzhou, Beijing, and Shanghai and is led by its CEO Dr. Ming Lv. Sumgen Biotech develops an integrated process covering drug discovery, manufacturing, and clinical development. The company's main product pipeline is focused on broad immuno-oncology targets, with SG001, SG301, SG404, and SG12473 projects in the clinical study stage. It also offers a technology platform for antibody discovery for bispecific antibodies and deployed abundant innovative pipelines in the tumor field.

Current Investors

CCB Private Equity Investment Management, China National Biotec Group Company Limited, Harmony Venture

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceuticals

Website

www.sumgenbio.com

Verticals

HealthTech, Manufacturing

Company Stage

Series B

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.